Q-omics provides the consensus-scored LINC01259 profile across patient tissues and cancer cell-line models. LINC01259 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, LINC01259 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, LINC01259 RNA expression shows 6,958 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCEC, KIRC, and THYM as cancer lineages where LINC01259 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01259 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01259 survival associations across molecular data types. LINC01259 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01259 RNA expression–survival associations across cancer types. High LINC01259 expression shows unfavorable associations in UCEC and COAD, but favorable associations in ESCA, LUAD, SKCM and PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for LINC01259 RNA expression.
This table summarizes LINC01259 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01259. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01259 shows lower tumor expression in LUSC and COAD and higher tumor expression in KIRC, STAD and BRCA. The KIRC box plot shows higher LINC01259 RNA expression in tumor versus normal tissue (log2 FC = +0.026, t-test p = .002).
This table shows molecular features associated with LINC01259 in patient tissues and cancer cell lines. In patient samples, LINC01259 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
